amivantamab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	October 04, 2024
Call for patient/clinician input closed	December 02, 2024
Submission received	February 20, 2025
Submission accepted	March 06, 2025
Review initiated	March 07, 2025
Draft CADTH review report(s) provided to sponsor for comment	May 26, 2025
Deadline for sponsors comments	June 04, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	June 26, 2025
Expert committee meeting (initial)	July 09, 2025
Draft recommendation issued to sponsor	July 23, 2025
Draft recommendation posted for stakeholder feedback	July 31, 2025
End of feedback period	August 15, 2025

Last Updated : July 31, 2025

Non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) mutation

Details

Review Type: Rapid

Provisional Funding Algorithm
Draft Report Posted:	31-Oct-2024
Stakeholder Feedback Deadline:	7-Nov-2024
Final Report Posted:	5-Dec-2024

Last Updated : December 5, 2024

durvalumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	02-Oct-24
Call for patient/clinician input closed	25-Nov-24
Submission received	15-Nov-24
Submission accepted	29-Nov-24
Review initiated	02-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	24-Feb-25
Deadline for sponsors comments	05-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	24-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25
Clarification: - Reconsideration: minor revisions requested by sponsor - Request for reconsideration accepted
Final recommendation issued to sponsor and drug plans	11-Aug-25
Final recommendation posted	-
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	25-Aug-25
CDA-AMC review report(s) posted	-

Last Updated : July 15, 2025

Pharmaceutical Reviews Update — Issue 51

Details

Program Updates

1. Update to Ethics Review Component of Complex Reviews

The description of the Ethics Review for Complex Reviews has been updated to further clarify the domains of ethical considerations explored within each review and the use of summary reports where appropriate. The linked Ethics Review Report template has been removed to reflect a customized approach to the reporting of ethical considerations based on the complexity of ethical issues present.

Last Updated : September 26, 2024

delgocitinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	19-Sep-24
Call for patient/clinician input closed	12-Nov-24
Submission received	25-Nov-24
Submission accepted	09-May-25
Clarification: - Submission was not accepted for review on 09 Dec 2024
Review initiated	12-May-25
Draft CADTH review report(s) provided to sponsor for comment	12-Aug-25
Deadline for sponsors comments	21-Aug-25
CDA-AMC review report(s) and responses to comments provided to sponsor	12-Sep-25
Expert committee meeting (initial)	24-Sep-25
Draft recommendation issued to sponsor	October 07, 2025 To October 09, 2025
Draft recommendation posted for stakeholder feedback	16-Oct-25
End of feedback period	30-Oct-25

Last Updated : May 12, 2025

Adult Classical Hodgkin Lymphoma - Provisional Funding Algorithm - Draft Report - PH0052

isatuximab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	17-Sep-24
Call for patient/clinician input closed	12-Nov-24
Submission received	30-Oct-24
Submission accepted	14-Nov-24
Review initiated	15-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	24-Feb-25
Deadline for sponsors comments	05-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	24-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25
Final recommendation issued to sponsor and drug plans	28-May-25
Final recommendation posted	13-Jun-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	11-Jun-25
CDA-AMC review report(s) posted	-

Last Updated : June 13, 2025

teprotumumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	12-Sep-24
Call for patient/clinician input closed	04-Nov-24
Submission received	25-Oct-24
Submission accepted	08-Nov-24
Review initiated	12-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	07-Feb-25
Deadline for sponsors comments	19-Feb-25
Clarification: - Voluntarily withdrawn by the sponsor

Last Updated : April 24, 2025

teprotumumab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 12, 2024
Call for patient/clinician input closed	November 04, 2024
Submission received	October 25, 2024
Submission accepted	November 08, 2024
Review initiated	November 12, 2024
Draft CADTH review report(s) provided to sponsor for comment	February 07, 2025
Deadline for sponsors comments	February 19, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	March 13, 2025
Expert committee meeting (initial)	March 26, 2025
Draft recommendation issued to sponsor	May 05, 2025
Draft recommendation posted for stakeholder feedback	May 22, 2025
End of feedback period	June 05, 2025
Clarification: - Reconsideration: major revisions requested by sponsor - Target CDEC reconsideration meeting date to be determined - Submission temporarily suspended

Last Updated : July 31, 2025

blinatumomab

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	September 06, 2024
Call for patient/clinician input closed	November 25, 2024
Submission received	October 18, 2024
Submission accepted	November 01, 2024
Review initiated	November 04, 2024
Draft CADTH review report(s) provided to sponsor for comment	January 31, 2025
Deadline for sponsors comments	February 07, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	February 28, 2025
Expert committee meeting (initial)	March 12, 2025
Draft recommendation issued to sponsor	March 25, 2025
Draft recommendation posted for stakeholder feedback	April 03, 2025
End of feedback period	April 17, 2025
Final recommendation issued to sponsor and drug plans	May 01, 2025
Final recommendation posted	May 20, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	May 15, 2025
CDA-AMC review report(s) posted	-

Last Updated : May 20, 2025